FDA critics offer data on "cozy" industry ties

News from the PDUFA reauthorization front: The FDA met with biopharma industry reps 112 times while reviewing drug policies while setting aside time for a total of five meetings with patient and consumer groups. BIO and PhRMA reps appear to have commanded the most quality time with the agency, which has been pushing Congress hard to reauthorize drug industry fees that are tied to agency deadlines on drug approvals. Critics used the information to highlight the "cozy" relationship biopharma enjoys with the FDA. For its part, the agency said it had a number of technical issues to work out on PDUFA that required the meetings.

- check out the report from USA Today

ALSO: Is the FDA emphasizing speed over safety? Report

Related Articles:
FDA chief defends collaboration in drug development. Report
FDA offers safety reforms to skeptical lawmakers. Report
Senate toughens drug safety supervision in PDUFA bill. Report
Congress juggles two crucial drug bills. Report
FDA, drug industry re-negotiate user fees. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.